STOCK TITAN
  1. Home
  2. Sec-filings
  3. TEVA
  4. [Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Tal Zvi Zaks of TEVA (NYSE: TEVA) converts 14,492 RSUs into ordinary shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.

Positive

  • None.

Negative

  • None.
Insider Zaks Tal Zvi
Role null
Type Security Shares Price Value
Exercise Restricted Share Units 14,492 $0.00 --
Exercise Ordinary Shares 14,492 $0.00 --
Holdings After Transaction: Restricted Share Units — 0 shares (Direct, null); Ordinary Shares — 73,264 shares (Direct, null)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
Shares acquired via RSU exercise 14,492 shares Restricted share units settled into ordinary shares on June 5, 2026
Post-transaction holdings 73,264 shares Ordinary shares directly held after the June 5, 2026 transaction
RSU-to-share ratio 1 unit : 1 share Each restricted share unit convertible into one ordinary share
ADS to ordinary share ratio 1 ADS : 1 ordinary share Each American Depositary Share currently represents one ordinary share
RSU grant date June 5, 2025 Grant date for the 14,492 restricted share units
RSU vesting date June 5, 2026 Vesting date when RSUs converted into ordinary shares
Restricted share units financial
"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion for the restricted share units"
contingent right financial
"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"
vested financial
"Restricted share units were granted on June 5, 2025 and vested on June 5, 2026"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zaks Tal Zvi
(Last)(First)(Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
(Street)
TEL AVIVISRAEL6944020
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/05/2026M14,492A(2)73,264D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Share Units(2)06/05/2026M14,492 (3) (3)Ordinary Shares(1)14,492$00D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
/s/ Dov Bergwerk as attorney-in-fact for Tal Zvi Zaks06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TEVA director Tal Zvi Zaks report on this Form 4?

Tal Zvi Zaks reported exercising equity awards, converting 14,492 restricted share units into 14,492 ordinary shares. This was a compensation-related derivative exercise rather than an open-market stock purchase or sale, reflecting vesting of previously granted share-based awards.

How many TEVA shares does Tal Zvi Zaks hold after this Form 4 transaction?

After the June 5, 2026 transaction, Tal Zvi Zaks directly holds 73,264 ordinary shares of TEVA. This total reflects the addition of 14,492 shares received from vested restricted share units and shows his updated equity stake following the award settlement.

What exactly happened to the 14,492 restricted share units reported by TEVA?

The 14,492 restricted share units granted on June 5, 2025 vested on June 5, 2026 and were settled into 14,492 ordinary shares. Each unit represented a contingent right to one share or its cash value, at the compensation committee’s discretion.

Did Tal Zvi Zaks buy or sell TEVA shares on the open market in this filing?

This Form 4 does not show any open-market buys or sells by Tal Zvi Zaks. It reports a derivative exercise, where vested restricted share units converted into ordinary shares as part of his equity compensation, with no sale of those shares disclosed.

When were the TEVA restricted share units granted and when did they vest?

The restricted share units reported in this Form 4 were granted on June 5, 2025 and vested on June 5, 2026. Upon vesting, the 14,492 units were settled into an equal number of ordinary shares as part of Tal Zvi Zaks’ compensation.